Medical device giant St. Jude Medical (NYSE:STJ) ended 2013 with a boost, notching a new Wall Street high-water mark of $63.15 on December 26.

Shares sank back down to close at $62.74 that day and have since dropped further to close at $61.71 today, but are still trading 4.6% higher than they were 1 month ago and 12.6% higher than 3 months ago.

St. Jude hit increasingly higher marks throughout December, rising to $59.88 on December 3, $59.96 on December 9, $60.78 on December 18 and then setting new highs every day until peaking on the 26th.

The gains come among a mixed bag of news for the Minnesota medtech titan, which last month canceled a renal denervation clinical trial on haggard enrollment, announced a $700 million share buyback and won European regulatory approval for another in its line of Portico heart valves.